Coma, respiratory depression, circulatory collapse, and pulmonary edema. Seizures occur more frequently in patients with propoxyphene intoxication than in those with opiate intoxication. LD50=230mg/kg (orally in rat, Emerson)
Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States. The drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. The levo-isomer appears to exhibit a very limited antitussive effect.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Dextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene. |
| Dronabinol | The serum concentration of Dronabinol can be increased when it is combined with Dextropropoxyphene. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene. |
| Hydrocodone | Dextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene. |
| Magnesium sulfate | The therapeutic efficacy of Dextropropoxyphene can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Dextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Dextropropoxyphene may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene. |
| Orphenadrine | Dextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Dextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene. |
| Pramipexole | Dextropropoxyphene may increase the sedative activities of Pramipexole. |
| Ropinirole | Dextropropoxyphene may increase the sedative activities of Ropinirole. |
| Rotigotine | Dextropropoxyphene may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Dextropropoxyphene. |
| Sodium oxybate | Dextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Dextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene. |
| Thalidomide | Dextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Dextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Alvimopan | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Alvimopan. |
| Desmopressin | The risk or severity of hyponatremia can be increased when Dextropropoxyphene is combined with Desmopressin. |
| Morphine | The risk or severity of adverse effects can be increased when Morphine is combined with Dextropropoxyphene. |
| Codeine | The risk or severity of adverse effects can be increased when Codeine is combined with Dextropropoxyphene. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dextropropoxyphene. |
| Oxycodone | The risk or severity of adverse effects can be increased when Oxycodone is combined with Dextropropoxyphene. |
| Naltrexone | The therapeutic efficacy of Dextropropoxyphene can be decreased when used in combination with Naltrexone. |
| Sufentanil | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Sufentanil. |
| Levorphanol | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Levorphanol. |
| Remifentanil | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Remifentanil. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Diphenoxylate. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Oxymorphone. |
| Dezocine | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dezocine. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methadyl acetate. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dihydroetorphine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Diamorphine. |
| Bezitramide | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Bezitramide. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethylmorphine. |
| Etorphine | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Etorphine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dextromoramide. |
| Desomorphine | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desomorphine. |
| Carfentanil | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Carfentanil. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dihydrocodeine. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Alphacetylmethadol. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dihydromorphine. |
| Ketobemidone | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ketobemidone. |
| DPDPE | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Lofentanil. |
| Opium | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Opium. |
| Normethadone | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Normethadone. |
| Piritramide | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Piritramide. |
| Alphaprodine | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Alphaprodine. |
| Nicomorphine | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Nicomorphine. |
| Meptazinol | The therapeutic efficacy of Dextropropoxyphene can be decreased when used in combination with Meptazinol. |
| Phenoperidine | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Phenoperidine. |
| Phenazocine | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Phenazocine. |
| Tilidine | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tilidine. |
| Carfentanil, C-11 | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Carfentanil, C-11. |
| Meperidine | The risk or severity of adverse effects can be increased when Meperidine is combined with Dextropropoxyphene. |
| Alfentanil | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Alfentanil. |
| Benzhydrocodone | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Benzhydrocodone. |
| Naloxegol | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Naloxegol. |
| Pegvisomant | The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dextropropoxyphene. |
| Succinylcholine | The risk or severity of bradycardia can be increased when Succinylcholine is combined with Dextropropoxyphene. |
| Eliglustat | The metabolism of Eliglustat can be decreased when combined with Dextropropoxyphene. |
| Ibrutinib | The metabolism of Ibrutinib can be decreased when combined with Dextropropoxyphene. |
| Cilostazol | The metabolism of Cilostazol can be decreased when combined with Dextropropoxyphene. |
| Colchicine | The metabolism of Colchicine can be decreased when combined with Dextropropoxyphene. |
| Fentanyl | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fentanyl. |
| Iloperidone | The metabolism of Iloperidone can be decreased when combined with Dextropropoxyphene. |
| Retapamulin | The metabolism of Retapamulin can be decreased when combined with Dextropropoxyphene. |
| Tofacitinib | The metabolism of Tofacitinib can be decreased when combined with Dextropropoxyphene. |
| Vardenafil | The metabolism of Vardenafil can be decreased when combined with Dextropropoxyphene. |
| Zopiclone | The metabolism of Zopiclone can be decreased when combined with Dextropropoxyphene. |
| Lovastatin | The metabolism of Lovastatin can be decreased when combined with Dextropropoxyphene. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Dextropropoxyphene. |
| Alfuzosin | The metabolism of Alfuzosin can be decreased when combined with Dextropropoxyphene. |
| Alprazolam | The metabolism of Alprazolam can be decreased when combined with Dextropropoxyphene. |
| Atomoxetine | The metabolism of Atomoxetine can be decreased when combined with Dextropropoxyphene. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Dextropropoxyphene. |
| Warfarin | The serum concentration of Warfarin can be increased when it is combined with Dextropropoxyphene. |
| Acenocoumarol | The serum concentration of Acenocoumarol can be increased when it is combined with Dextropropoxyphene. |
| (R)-warfarin | The serum concentration of (R)-warfarin can be increased when it is combined with Dextropropoxyphene. |
| R,S-Warfarin alcohol | The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Dextropropoxyphene. |
| S,R-Warfarin alcohol | The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Dextropropoxyphene. |
| (S)-Warfarin | The serum concentration of (S)-Warfarin can be increased when it is combined with Dextropropoxyphene. |
| Midazolam | The serum concentration of Midazolam can be increased when it is combined with Dextropropoxyphene. |
| Tacrolimus | The serum concentration of Tacrolimus can be increased when it is combined with Dextropropoxyphene. |
| Atorvastatin | The metabolism of Atorvastatin can be decreased when combined with Dextropropoxyphene. |
| Mirabegron | The serum concentration of Dextropropoxyphene can be increased when it is combined with Mirabegron. |
| Mirtazapine | Dextropropoxyphene may increase the serotonergic activities of Mirtazapine. |
| Fluvoxamine | The risk or severity of serotonin syndrome can be increased when Dextropropoxyphene is combined with Fluvoxamine. |
| Citalopram | The risk or severity of serotonin syndrome can be increased when Dextropropoxyphene is combined with Citalopram. |
| Duloxetine | The risk or severity of serotonin syndrome can be increased when Dextropropoxyphene is combined with Duloxetine. |
| Sertraline | The risk or severity of serotonin syndrome can be increased when Dextropropoxyphene is combined with Sertraline. |
| Sibutramine | The risk or severity of serotonin syndrome can be increased when Dextropropoxyphene is combined with Sibutramine. |
| Zimelidine | The risk or severity of serotonin syndrome can be increased when Dextropropoxyphene is combined with Zimelidine. |